- Home
- ABTC vs PBYI Comparison
ABTC vs PBYI Comparison
Compare ABTC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTC | PBYI |
|---|---|---|
| Founded | 2024 | 2010 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.3M | 403.6M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | ABTC | PBYI |
|---|---|---|
| Price | $6.17 | $7.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 327.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $79.69 | N/A |
| Revenue Next Year | $50.64 | N/A |
| P/E Ratio | $5.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $3.05 |
| 52 Week High | $10.24 | $8.75 |
Technical Indicators
Market Signals| Indicator | ABTC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout ABTC American Bitcoin Corp.
American Bitcoin Corp is a Bitcoin accumulation platform that integrates scaled Bitcoin mining operations with disciplined accumulation strategies. Its business is engaged in the operation of application-specific integrated circuit ("ASIC") miners for mining Bitcoin and the strategic accumulation of a Bitcoin reserve.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.